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ABSTRACT
SELF-ASSEMBLED GOLD NANOPLEXES FOR
CANCER-TARGETED SIRAN DELIVERY
by Yongliang Shi
August 2014
Through layer-by-layer method, the authors have constructed three Au
nanoplexes: AuPEI/RNA/PEI, AuPEI/RNA/PEI-mPEG, and AuPEI/NA/PEI-PEG-FA.
All the nanoplexes are characterized by UV-vis spectrometry, DLS, and zeta potential.
The surface density of the first layer PEI and second layer RNA were also determined.
Moreover, the Au nanoplexes can protect siRNA from RNase degradation and are stable
in cell culture medium.
siGLuc-ppp, ssRNA80, and siF17 were delivered by the assembled Au
nanoplexes, and the results were analyzed by GLuc assay, TB assay, and Luciferase
assay. In terms of RNA delivery, the Au nanoplexes AuPEI/RNA/PEI exhibited excellent
gene silencing efficiency (or causing severe cell death) in the absence of the serum during
the transfection. In terms of targeted delivery, PEGylation greatly reduces the nonspecific
delivery of siRNA caused by AuPEI/siRNA/PEI. However, no apparent difference is
found between AuPEI/RNA/PEI-mPEG and AuPEI/RNA/PEI-PEG-FA.
Fast fabrication, versatility, and ability for siRNA protection are the major
characters of our new developed Au nanoplex system. The high gene silencing efficiency
in the absence of serum makes it an excellent delivery agent for negative-charged
macromolecules in vitro. However, the application of the system in targeted delivery
needs more exploration.
ii
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CHAPTER I
INTRODUCTION
The Potential of siRNA for Cancer Therapeutics
Traditional Cancer Treatment and the Limitations
Cancer is the general name for a group of more than 100 diseases characterized by
the uncontrolled growth and spread of abnormal cells. Although there are many kinds of
cancer, they all start because abnormal cells grow out of control.1 The American Cancer
Society estimated that in 2013, about 1,660,290 new cancer cases are expected to be
diagnosed, and about 580,350 Americans are expected to die of cancer. Cancer has
already become the second most common cause of death, exceeded only by heart
disease.1
Traditional treatment of cancer includes surgery, radiation, and chemotherapy.
Unlike radiation and surgery that are considered as local treatments, chemotherapy,
defined as the use of chemicals to treat disease cancer, is almost always used as a
systemic treatment: the chemicals travel through the body to the cancer cells.2 The
benefits of systemic treatment are the rapid action and biodistribution as well as the wide
application to the inaccessible tissues for local treatment. Therefore, more than 100 drugs
are used today for chemotherapy, either alone or in combination with other drugs or
treatment.1
Although widely used in cancer therapy, conventional chemotherapy, which
utilizes small molecular drugs, is far from successful. This problem mainly derives from
their lack of tumor selectivity or so-called selective toxicity of these agents.3 When the
drugs attack tumor cells, they cannot tell the difference between cells of normal tissues
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and cancer cells. Therefore, they cause damage on both of them. The normal cells that are
most likely to be damaged are those that divide rapidly: bone marrow/blood cells, cells of
hair follicles, cells lining the digestive tract, and cells lining the reproductive tract.1 As a
result, patients getting chemotherapy suffer from various severe and painful side effects,
such as nausea and vomiting, hair loss, fatigue, and damage to the heart, nervous system,
and lungs.1
Resistance to traditional chemotherapy is another problem for the chemotherapy.
When chemotherapy was first introduced into clinical practice by Gilman in the 1940s,
resistance, as Paul Ehrlich said, had already followed as a faithful shadow.4 They found
the tumor did not respond to the chemotherapeutic agent any more when the third
treatment was applied.5 Since then, resistance to cancer chemotherapy becomes a
common phenomenon, especially in progressive disease. The most major reason for the
acquisition of multidrug resistance in cultured cancer cells was the expression of one or
more energy-dependent drug efflux pumps, which can detect and eject anticancer drugs
from cells.6 For example, P-glycoprotein (permeability glycoprotein, abbreviated as Pgp), a well-characterized ATP-binding cassette transporter (ABC-transporter), is usually
unregulated in many untreated, intrinsically drug-resistant tumors.7 P-gp detects and
binds hydrophobic natural-product drugs, such as doxorubicin, vinblastine, and
antiarrhythmics8, and then releases them into the extracellular space.9 Other reasons for
resistance include reduced uptake of the drugs, insensitivity to drug-induced apoptosis,
and induction of drug-detoxifying.6
“Targeted cancer therapies” were then introduced to the cancer treatment. The
concept involves the drugs or substances that can specifically target the tumor cells and
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block the growth and spread of cancer. Two main strategies are utilized right now. One is
called the “functionality-targeted” strategy, which target the key molecules in the specific
novel pathway in the cancer cell. One famous example is the Gleevec that is used to treat
certain types of leukemia. Another is called “ligand-targeted strategy,” which take
advantage of the overexpression of specific ligand in the cancer cell surface to deliver the
drugs specifically to cancer cells. RNA interference (RNAi), the Nobel Prize-winning
discovery in 2006, provides a brand new mechanism for the “functionality-targeted”
strategy, and small interfering RNA (siRNA) is proposed as the next generation of anticancer drug. In the introduction, I will present the potential and limitations of siRNA and
the current status of development of non-viral vectors for siRNA delivery. Finally, I will
discuss a specific “ligand-targeted strategy,” folate receptor mediated targeted delivery.
The Mechanism of RNAi
To this point, the picture about the RNAi mechanism becomes clear (shown in
Figure 1). Combined with the later studies, the RNAi pathway was summed up as
followed: the RNAi pathway located in the cytoplasm of the cell consists of two phases:
the initiation phase (generation of effector molecules) and the subsequent effector phase
(the actual RNAi mechanism). The effector molecules can be divided into two types:
small interfering RNA (siRNA) and micro RNA (miRNA). In general, siRNA is a 21-23
nucleotides (nt) double-stranded RNA (dsRNA) with two nucleotide 3’- overhangs and
micro RNA usually comprises 22 nt dsRNA segments. siRNA is produced from the
cleavage of long dsRNA by Dicer (a multi-domain enzyme of the RNase III family) in
the cytoplasm while microRNA is produced in the nucleus where endogenously encoded
primary miRNA transcripts (pri-miRNA) are processed into precursor miRNA (pre-
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miRNA) and then transported into the cytoplasm where it is cleaved by Dicer. In the
effector phase/second stage, both of the siRNA and miRNA are unwound, and only
single-stranded (antisense) siRNA or miRNA is assembled into RNA-induced silencing
complexes (RISC). With its guidance, RISC targets its complementary mRNA. Another
difference between siRNA and microRNA is whether they have perfect sequence
complementarily with its target messenger RNA (mRNA). siRNA binds its target with a
perfect match and induces site-specific cleavage of the mRNA while miRNA binds its
targets with a typically imperfect match and induces translational repression rather than
mRNA degradation. Both of the pathways result in the inhibition of protein synthesis.

Figure 1. Mechanism of RNA interference.
Advantages and Challenges of RNAi-based Therapy
Shortly after the demonstration of sequence-specific knockdown in mammalian
cell by synthetic siRNAs10, McCaffey showed that they could also induce the suppression
of the transgene expression in adult mice, and the specific and effective targeting of a
sequence from hepatitis C virus by RNAi in vivo indicated the therapeutic potential of
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this technique.11 Since then, considerable efforts in the advancement of siRNA
therapeutics were made for the treatment of various disease targets, including cancer.12
Firstly, siRNA has broader therapeutic potential than typical chemotherapy drugs.
According to the RNAi mechanism, as long as the siRNA is designed appropriately, the
RNAi machinery can be exploited to knock down any gene, expanding the universe of
drugable targets to the entire genome.13 For cancer, these genes include oncogenes/antiapoptotic molecules or other survival factor, telomerase, growth factor receptor genes,
key molecules in signaling pathways or genes essential for cell proliferation, and many of
those are not considered viable conventional drug targets.14 Moreover, these new types of
drug targets could also, in principle, eliminate the cancer stem cells within a tumor or
within other tumor cells that are relatively resistant to chemotherapy and radiation.13
The second reason is the high degree of specificity of siRNA targeting. Since
many current drug targets are proteins with similar 3D structures, for example, the
protein kinases, phosphatases and proteases, it is very difficult to develop smallmolecular drugs that are specific for a single family member.
Despite the promise of RNAi for cancer therapy, some hurdles must be
confronted to bring small RNAs into the clinic.
Systemic Elimination of siRNA
From the view of drug delivery, negative charges, large molecule weight and size,
and instability of the naked siRNA molecules are unfavorable physicochemical properties
which leads to short plasma half-life of <10 min.15 Chemical modifications of the RNA
backbone and the use of nano-sized carriers partially overcome these problems.16
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Entrapment in reticuloendothelial system.17 Since naked siRNA is seldom applied
in systemic delivery, carrier systems are devised to protect siRNA from undesirable
interaction with biological milieu components and from metabolism or degradation.
However, after systemic administration, carriers are rapidly distributed to organs in the
reticuloendothelial system (RES) and phagocytosed by the mononuclear phagocyte
system, resulting in higher particle accumulations in RES organs, such as liver and
spleen, relative to non-RES organs.
Vascular Endothelial Barrier.18 Within an organ, siRNA or carriers undergo
extravasation and enter the interstitium. Transport across vessel walls can occur via
diffusion, convection through capillary pores, and transcytosis. In general, capillary pore
size limits the upper size for the extravasated particulates. The pore size of tumor
microvessels ranges from 100 to 780 nm in diameter. In comparison, microvessels in
most normal tissues are less leaky. The tight junctions between endothelial cells are
usually < 2 nm, and the pore size in post-capillary venules is < 6 nm, whereas fenestrated
endothelium of the renal glomeruli and the sinusoidal endothelium of the liver and spleen
show larger pore sizes of 40–60 and 150 nm, respectively. Due to vessel leakiness, the
major pathway of drug transport across tumor microvascular wall is by extravasation via
diffusion and/or convection through the discontinuous endothelial junctions, whereas
transcytosis plays a relatively minor role.
Transport in Tissue Interstitium.19 Transport of small molecules in the interstitial
space is mainly by diffusion, whereas transport of large molecules is mainly by
convection. Diffusion depends on the diffusivity and concentration gradient, and
convection depends on the hydraulic conductivity and pressure difference. For tumors,
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due to the higher interstitial fluid pressure compared to normal tissues, the pressuredriven convective flow in tumor interstitium is outward from the core of a tumor into the
surrounding normal tissues. The lack of a lymphatic system in solid tumors increases
interstitial fluid pressure, thereby inhibiting the convective transport in tumor interstitial
space.
Internalization of siRNA in cells.20 The major mode of internalization is
endocytosis. The drug molecules are internalized together with a component of the cell
membrane. Because of the high molecular weight, large size, and negative charges of the
phosphate backbone, it is hard for naked siRNA to cross the anionic cell membrane by
passive diffusion. The positively charged siRNA–carrier complex interacts with anionic
proteoglycans on the cell surface, forms an endocytic vesicle, and enters the cells by
endocytosis. Coating of carriers with ligands and antibodies can promote the carrierspecific binding to cell membrane.
Transport of siRNA within cells.21 Following cellular internalization, the siRNA –
carrier complex (in endocytic vesicles) is transported along microtubules to lysosomes.
The fate of the internalized molecules inside the vesicle depends on the specific type of
receptors and includes the following: recycled to the cell surface, degraded inside
lysosomes, or released to other intracellular compartments including the cytosol. The
endosomal entrapment and lysosomal degradation of siRNA-carrier contributes to the
low transfection efficiency and is a major impediment for non-viral carriers.
Non-viral Vectors for siRNA Delivery
Viral vector based carriers and non-viral carriers are two main approaches to
achieve cellular delivery of siRNA. The difference between the two is that viral vector-
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based siRNA expressing cassettes provide a lasting RNAi effect, and non-viral systems
only offer transient RNAi effects.22 And the highly efficient delivery of the former make
them the most powerful tools for transfection so far. However, their clinical application is
limited by the invocation of immunogenic response, high cost of manufacturing, and the
lack of cell specificity.23 The following section mainly focuses on the non-viral carriers.
Polyethylenimine (PEI)
Polyethylenimine (shown in Figure 2), often considered the gold standard of gene
transfection, is one of the most prominent examples of cationic polymers capable of gene
transfection.24
In 1995, Behr first utilized branch PEI as the vector for gene and oligonucleotides
transfer.25 The motivation was that they were trying to look for a substitute that had
similar DNA-condensing and pH-buffering properties to polyamidoamine (PAMAM) and
lipopolyamines. PEI was selected due to its high cationic-charge-density and the
buffering capacity at virtually any pH. Luciferase assay gave results comparable to or
even better than lipopolyamines, and cytotoxicity was low and seen only at
concentrations well above those required for optimal transfection. Combined with other
results, the authors concluded that PEI was a promising vector for gene therapy and an
outstanding core for the design of more sophisticated devices.25
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Figure 2. Chemical structure of PEI at neutral pH.
Two years later, Behr proposed “proton-sponge hypothesis” to explain the
remarkable transfection properties of PEI.26 The buffering capacity of PEI came from its
unique structure: in every third position was an amino group so the overall protonation
level increased from 20 to 45% between pH 7 and 5. Once the PEI/DNA complexes
entered the cell by endocytosis, a high local concentration of PEI would be produced in
the endosome. During the intracellular trafficking, the buffering capacity of PEI would
inhibit the action of lysosomal nucleases that had an acid optimal pH and change the
osmolarity of vesicle. The protons would also be accumulated. As a result, the ionic
concentration within the endosome would increase considerably, which would result in
the osmotic swelling of the endosome. Furthermore, the polymeric network would be
expanded by the internal charge repulsion. Hence, the endosomal life would be greatly
reduced, so the DNA would rapidly escape from the damaging endosomal environment.26
By supported by further studies 27 28, the theory has gained widespread acceptance despite
challenges to the hypothesis.24
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Effect of the Molecular Weight of PEI
The effect of the molecular weight and the size of PEI on the transfection
efficiency were studied.29 PEIs with nominal molecular weights of 600, 1200, 1800,
10,000, and 70,000 Da were examined at a pH of 5.0, 6.0, 7.0, and 8.0. They found the
transfection efficiency was increased when the molecular weight of PEI increased. PEIs
of lower molecular weights (< 1800 Da) produced no transfection at all. In contrast, the
pH of the PEI solutions had no discernible effect on transfection.
The magnitude of the cytotoxic effect of PEI was found to be time and
concentration dependent.30 The molecular weight and the cationic charge density were
the key parameters for interaction with cell membranes and consequently, the cell
damage. High molecular weight polymers result in significantly higher cytotoxicity.30
Hence, taking both efficiency and toxicity into consideration, the optimal molecular
weight for PEI polyplex formation is typically between 5 and 25kDa.31
Effect of the Degree of Branching of PEI
In addition to molecular weight, the degree of branching of PEI could also
influence the complex formation, transfection efficiency, and in vitro toxicity. Dunlap
demonstrated that the branch form appeared to be a more effective condensing agent,
compared with the linear PEI with similar molecular weight.32 The binding ability and the
complex stability could also be correlated with the number of primary amines, for they
were highly protonated at a given pH.33 34 High branched PEIs achieve higher
transfection efficiency due to the formation of smaller size of polyplexes but also
possessed a higher toxicity.35
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Functionalized PEIs
Various chemical modifications of PEI structure have been employed in an effort
to reduce the cytotoxicity while maintaining or improving transfection efficiency (shown
in Figure 3).
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Figure 3. Various functionalized branched PEI.
With the initial purpose of investigating the effects of protonation properties of
PEI, Forrest synthesized PEI derivatives by acetylating varying fractions of the primary
and secondary amines to form secondary and tertiary amides.36 Acetylation of PEI
decreased the buffering capacity, zeta potential, and increased the diameter of the
polyplex. Surprisingly, acetylation had a negligible effect on cytotoxicity of the polymers
and increased gene delivery effectiveness by up to 21-fold compared to unmodified PEI,
both in the presence and absence of serum.36 Furthermore, Zintchenko introduced the
negatively charged propionic acid or succinic acid group to the polymer structure.37
Formulations of siRNA with succinylated PEI were able to induce remarkable
knockdown of the target luciferase gene at the lowest tested siRNA concentration of 50
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nM. In particular, succinylation of branched PEI resulted in up to 10-fold lower polymer
toxicity in comparison to unmodified PEI.37
To combine the advantages of both liposomes and cationic PEI, Kim synthesized
the water soluble lipopolymer (WSLP) which consisted of a positively charged headgroup of low molecular PEI and hydrophobic lipid group of cholesterol.38 The PEI
component condenses DNA and enhances the transfection efficiency by escaping DNA
complexes from degradative endosome or lysosome compartments, while the lipid
coating on the complex increases its permeability through cell membranes. The WSLP
showed low cytotoxicity and high transfection efficiency as compared with highmolecular-weight and non-modified PEI.39 Borrowing the similar strategy, Philipp
modified low molecular weight oligoethylenimine (OEI) with hydrophobic alkyl
acrylates. The optimal structure was the conjugate containing ten hexyl acrylate residues
per one OEI chain.40 Chen designed and synthesized copolymer by grafting hydrophobic
poly (γ-benzyl L-glutamate) segment (PBLG) to hyperbranched PEI, which exhibited
lower cytotoxicity in comparison to unmodified PEI.41
It was well known that PEG (polyethylene glycol) could be used as a stabilized
agent, which could shield the positive charge of the surface of the particles in order to
avoid rapid systemic clearance. Hence, Mao synthesized PEI-graft-PEG block
copolymer/siRNA polyplexes and investigated the effect of PEG chain length on their
physicochemical and biological properties.42 In agreement with their hypothesis,
PEGylation could modify the stability of PEI/siRNA polyplexes. The release of siRNA in
the cytosol depended on polyplex stability and protection against RNase digestion. A
good correlation between RNase stability and knockdown efficiency in cell culture was
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found for the polyplexes studied.42 Further study showed that the optimal PEG-PEIsiRNA complex had a prolonged siRNA blood circulation time and reduced nonspecific
uptake into the liver, spleen and lung as compared with those of non-PEGylated PEIsiRNA complex and naked siRNA.39 43
Bioresponsive Smart carrier system
As discussed above, both the efficacy and toxicity of PEI are strongly correlated
with its molecular weight as well as the degree of branching. It seems that efficacy and
side effects were strongly associated.44 To close this gap, Berunig synthesized disulfide
cross-linked low molecular-weight linear PEI/pDNA complexes (shown in Figure 4A)
that were reductively degradable inside cells so that their charge density could be
diminished to levels that minimized the risk of interactions with cellular components and
therefore, exert significantly less toxicity.44 Investigations with these materials revealed
that the extracellular high MW provided outstandingly high transfection efficacies while
the intracellular reductive degradation produced mainly nontoxic fragments. Compared
with seven commercial transfection reagents in seven different cell lines, the degradable
polymers showed highly superior transfection efficacies and substantially lower
toxicities.44
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Figure 4. Structure of polycations bearing sensitive linkage for building smart carrier
systems.
Borrowing the similar strategy, Kim synthesized a bio-reducible cationic polymer,
arginine-conjugated poly (cystaminebisacrylamide-diaminohexane) (poly (CBA-DAHR)) (shown in Figure 4B) as the siRNA carrier for therapeutic gene silencing for cancer.45
After intracellular uptake of the siRNA/poly (CBA-DAH-R) polyplexes, the disulfide
linkages in the polymeric backbone were cleaved in the reductive environment of the
cytoplasm. As a result, the siRNA/poly (CBA-DAH-R) polyplexes were decomplexed,
and siRNA molecules were released throughout the cytoplasm. With arginine
modification, the siRNA/poly (CBA-DAH-R) polyplexes were demonstrated to possess
increased membrane permeability and had a similar level of cellular uptake as siRNA/PEI
polyplexes. However, the VEGF siRNA/poly (CBA-DAH-R) polyplexes, inhibited
VEGF expression to a greater degree than VEGF siRNA/PEI in various human cancer
cell lines due to the enhanced intracellular delivery and effective localization to the
cytoplasm of the VEGF siRNAs.45
Another example that utilized the disulfide cross-linking was presented by
Matsumoto.46 They prepared a core-shell type polyion complex micelle with a disulfide
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cross-linked core though the assembly of iminothiolane-modified poly (ethylene glycol)block-poly (L-lysine) [PEG-b-(PLL-IM)] (shown in Figure 4C). The micelle was further
mixed with siRNA at the optimum ratio. The resulting complexes showed a spherical
shape of ∼60 nm in diameter with a narrow distribution. The micellar structure was
maintained at physiological ionic strength but was disrupted under reductive conditions
due to the cleavage of disulfide cross-links, which is desirable for siRNA release in the
intracellular reductive environment. And it was worth noting that environment-responsive
micelles achieved 100-fold higher siRNA transfection efficacy compared with non-crosslinked PICs prepared from PEG-b-poly (L-lysine).46
Gold Nanoparticles
Gold nanoparticles (AuNPs) have a rich history in chemistry. As early as Roman
times, people had used them to stain glasses for decoration. However, the modern era of
AuNP synthesis actually started over 150 years ago.47
In 1857, Michael Faraday first synthesized colloidal gold by the reduction of gold
chloride in the presence of sodium citrate, a stabilizing agent.47 In the 1950s, these
particles were found to bind protein biologics without altering their activity and were
further used in handheld immunodiagnostics and in histopathology.48 Later on, the
radioactive colloidal AuNPs, made from Au198, were used to treat liver cancer and
sarcoma. Drug-associated toxicities were observed due to radiation exposure while no
toxicities were noted form the particles themselves.48 In the 1990s, AuNPs were
assembled into macroscopic aggregates for DNA diagnostics and biosensor.49
In recent years, the unique chemical and physical properties of AuNPs are
exploited for caner-selective photothermal therapeutics, non-invasive diagnostic imaging,
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transporting, and unloading pharmaceuticals50 51: 1) The strong resonant light-absorbing
of AuNPs results in strong, highly localized photothermal heating upon laser
illumination, an effect could be used to induce cancer cell death and tumor remission.52 2)
The optical resonance of AuNPs could be tuned to any wavelength of interest by
manipulating their shape and size.52 3) The spherical AuNPs were not inherently toxic to
human cells, despite being taken up into cells.53 4) They are easily synthesized, and they
are readily functionalized generally through thiol linkages.51 5) Their photophysical
properties could trigger drug release at remote place.54
Layer-by-layer Approach for Assembly of AuNPs for siRNA Delivery
Lay-by-Layer (LbL) strategy was earlier utilized for fabrication of thin films on
flat solid surfaces and microparticles. In 2009, Elbakry explored the feasibility of LbL to
assemble AuNPs for siRNA delivery.55 Shown in Figure 5, the AuNP/PEI/siRNA/PEI
complex was prepared through deposition of oppositely charged polyelectrolytes layer by
layer. The particles was characterized at each step, and the cellular uptake and gene
silencing of the final particles were studied, providing valuable information to detect
existing limitations and to design new materials for siRNA delivery.55
The author found that under appropriate polyelectrolyte concentration and ionic
strength, the majority of AuNPs remained single particle. The hydrodynamic diameter of
the intermediates and the final complex were smaller than 30 nm. After each coating, the
AuNPs exhibited a charge reversal. The number of siRNA molecules was calculated to be
around 780 siRNA molecules per particle. The further characterization of AuNPs in the
serum-containing culture showed that the zeta potential of all particles types was
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negative. The result of incubation of particles in the serum-free medium supported the
hypothesis that serum proteins were necessary for stabilization of the nanoparticles.55
The study of cellular uptake of AuNPs showed that the number of siRNA/PEIAuNPs per cell was 4 times more than that of PEI/siRNA/PEI, which suggested surface
properties may strongly affect interactions with cells, for the AuNPs were of nearly
similar size. However, in the gene silencing experiment, when siRNA was used as the top
layer, no silencing efficacy was detected, while PEI/siRNA/PEI-AuNPs induced 72%
knock-down efficacy of the cellular EGFP (enhanced green fluorescence protein)
production. Finally, the cell viability assay showed PEI/siRNA/PEI-AuNPs had no
serious toxicity in cell culture.55
PEI
MUA
AuNPs

MUA

MUA
PEI

AuNPs

AuNPs

PEI

PEI
siRNA
PEI

MUA

MUA

siRNA

AuNPs

PEI

siRNA

AuNPs

Figure 5. Flowchart illustrating the LbL deposition applied to AuNPs.
Later on, borrowing the LbL strategy, different forms of Au nanoparticles were
synthesized: PEI capped AuNP/siRNA56, cysteamine capped AuCM/siRNA/PEI/HA (HA
= hyaluronic acid)57, multilayered siRNA-coated AuNPs58, and AuNP/PEI/PAHCit/PEI/siRNA (PAH-Cit = cis-aconitic anhydride-functinalized poly (allylamine)).59
These systems can be divided into three groups by the surface properties: 1) the top layer
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is positive charge polymer, for example, the multilayered siRNA-coated AuNPs, the top
layer was PLL; 2) the top layer is siRNA, such as PEI capped AuNP/siRNA and
AuNP/PEI/PAH-Cit/PEI/siRNA; 3) negative charged polymer: AuNP/siRNA/PEI/HA.
Their physiochemical properties are summarized in Table 1.
Table 1
Characterization of Different AuNPs Complexes
Positive
charged
polymer

siRNA

AuNP/PLL/siR
NA/PLL/siRN
A/PLL/siRNA/
PLL

AuNP/PEI/siRN
A

AuNP/PEI/PAHCit/PEI/siRNA

AuCM/siR
NA/PEI/H
A

183 nm

51 nm/18 nm

Not available

166 nm

Zeta
40 mV
potential

-16 mV/12 mV

Not available

-12 mV

siRNA
per
AuNP

Not available

Not available

44

Top
layer

H.D.

Not available

Negative
charged
polymer

H.D. = hydrodynamic diameter; AuCM = cysteamine capped AuNPs

Because of interparticle bridging and aggregation, the hydrodynamic diameter of
the final AuNPs varied in a wide range. If we take a close look at the data they published
(not shown in the table), we could find that when the AuNP was coated with siRNA
layer, the size increased a lot: the diameter of AuNP/PLL/siRNA increased 60 nm,
compared with AuNP; AuNP/PEI/siRNA with zeta potential of -16 mV increased 40 nm,
in comparison with AuNP/PEI; AuCM/siRNA even increased 80 nm compared with
AuCM alone. Although the above authors used the same strategy, the hydrodynamic
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diameters were not consistent with each other. Besides, the siRNA per particles varied
much too. It seemed that the positive charge surface could keep the AuNP remain single.
Biocompatibility and Biodistribution of AuNPs
When designing the anti-cancer AuNPs conjugates, stability is one significant
aspect, for high ionic concentration are present in both physiologic fluids and cell growth
media. The reason why the suspended AuNPs are relatively stable is that the working
distance of their repulsive forces outweighs that of their attractive forces. Repulsive
forces are generally determined by the surface charge of AuNPs (electrostatic repulsion)
or related with physical separation, such as steric separation, while attractive forces are
usually due to van der Waals interactions. In the physiological environment, electrostatic
repulsion alone is often not enough to overcome Debye charge screening and subsequent
nanoparticles aggregation. Therefore, to allow stable suspension of the particles in both
high ionic strength and serum concentration environments, further surface modification
of AuNPs is necessary.50
One strategy is to use the hydrophilic polymer to achieve physical separation. As
mentioned above, PEG is the most common used surface ligand for stabilization and
extended circulation time. Borrowing the same strategy, Maltzahn synthesized PEGprotected gold nanorods that exhibit superior circulation half-life in vivo as high as 17 h,
compared with the prototypical particles.60 Other common polymers used for physical
isolation include poly (lysine) (PLL), poly-(styrene sulfonate) (PSS), and poly
(vinylpyrrolidone) (PVP).50
When tumor cells grow to certain level, angiogenesis is induced for the tumor’s
requirements for a large amount of nutrition and oxygen. Compared with normal
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vasculature, the blood vessels in the tumor are irregular in shape, dilated, leaky and
defective, which further results in extensive leakage of blood plasma components, such as
nanoparticles, into the tumor tissue. Because of the slow venous return in tumor tissue
and the poor lymphatic clearance, the nanoparticles are retained in the tumor and then
spread into tumor interstitium. This phenomenon is termed as the enhanced permeability
and retention (EPR) effect.57
Of the tumor targeting, the EPR effect is a key mechanism for solid tumor
targeting and considered a gold standard for novel drug design.56 Based on this effect,
anti-cancer gold nanoparticles conjugates could achieve size-selective accumulation at
tumor sites. The optimal size depends on the stage, location, and type of cancer.
Theoretically, the hydrodynamic diameter of a particle should be larger than 6 nm (renal
clearance threshold) and smaller than 2 um.50 Studies showed that gold nanoparticles
exhibited 2-5% tumor accumulation by EPR effect.50
To maximally accumulate AuNPs in cells, Chithrani investigated the intracellular
uptake of different sized and shaped colloidal AuNPs in cervical cancer cells.61 They
found the kinetics and saturation concentrations were highly dependent upon the physical
dimensions of the nanoparticles (NPs), and 50 nm NPs had the shortest uptake half-life.61
In another study, Jiang studied how cells interacted with NP of a well-defined
sized at the molecular level.62 They showed that AuNPs coated with antibodies could
regulate the process of membrane receptor internalization, and the binding and activation
of membrane receptors strongly depended on their size. 40-and 50-nm NPs demonstrated
the greatest effect.62
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Moreover, NPs with positive surface charge could also promote the uptake
because of the electrostatic attraction with anionic cell-surface proteolycans. However,
similar to cationic lipoplexes and polyplexes, significant cytotoxicity was observed due to
membrane disruption. Lipophilicity could also further promote the nanoparticles-cellular
interaction and uptake but also resulted in poor aqueous stability and low circulatory halflife.50
Another key aspect in the design of anti-cancer gold nanoparticles conjugates is
the pharmacokinetic clearance of circulating AuNP conjugates. Poly-anionic AuNPs up
to 4-6 nm in hydrodynamic diameter typically exhibit efficient urinary excretion but often
exhibit decreased cell penetration. Poly-cationic AuNPs with up to 6-8 nm in could be
efficient cleared due to electrostatic attraction with the net negative charge of the
capillaries. However, they have a poor circulatory half-life. When AuNPs were neutral in
zeta potential and contained hydrophilic polymers such as PEG, they exhibited the lowest
opsonizaiton and phagocytic uptake.50
Application of AuNPs in Cancer Therapeutics
Giljohann et al. attached siRNA directly to the surface of AuNPs via an PEGthiol, and the conjugate had an inhibitory effect on luciferase expression in a luciferaseexpressing cell line.63 Lee et al. also directly attached siRNA to AuNPs and further
modified the conjugate with poly (b-amino ester) to convey positive charge and enhance
cellular uptake.64 Recently, Braun et al. developed a near-infrared laser-controlled
siRNA-release AuNP, which involved three layers: AuNP was firstly coated with thiolPEG conjugated to siRNA, secondly covered with lipid, and thirdly decorated with TAT-
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lipid. Laser irradiation cleaved the attachment of the thiol on the AuNP surface, so
siRNA was released from AuNP depending on the intensity of the laser irradiation.
Folate-mediated Delivery
Two strategies for tumor-targeted therapies: the first one is to selectively block
novel pathways or proteins that emerge or become over-expressed in malignant cells; the
second one involves the use of a homing ligand that binds specifically to a receptor that is
expressed primarily on malignant cells.65
Ligand-targeted therapies offer several advantages over the aforementioned
functionality-targeted therapies, the most notable being the remarkable flexibility and
adaptability. Almost any potent drug can be targeted to a tumor tissue if it can be linked
reversibly to a targeting ligand with specificity for a pathologic cell type.65
Folic acid (FA) is a vitamin that is essential for the proliferation and maintenance
of all cells. There are two mechanisms for the cells to internalize the folic acid66 67: direct
transport68 and endocytosis.68 69 The expression of folate receptor (FR) isoforms (FR-α
and FR-β) depends on tissues and differentiation states.70 71
Normal tissues usually do not express detectable FR72, but high levels of FR are
often over-expressed by epithelial cancer cells.66 67 And this high level expression of FR
by epithelial cancer cells provides an excellent mechanism for target-mediated (receptortargeted) imaging and therapeutic.73
Since the discovery of an efficient delivery of folate-macromolecule conjugates
via FR-mediated endocytosis74, a varity of molecular functionalities have been
successfully linked to FA to achieve FR-targeted delivery to tumor cells.75 76 63 77 Other
examples includes folate-conjugated dendrimers78 79, anti-GFP siRNA that is delivered to
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KB cells to achieve suppression of GFP expression80 81, folate-siRNA that delivers
siRNA into KB cells82, and folate-linked lipid nanoparticles.83
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CHAPTER II
SIGNIFICANCE AND OBJECTIVES
Significance
Nowadays, most of the AuNP/siRNA delivery systems have positive-charged
surfaces and are nonspecific. Similar to the positive lipoplexes and polyplexes discussed
above, the cationic portrait would cause the rapid clearance from the circulation and
significant toxicity because of membrane disruption, although it could also promote the
uptake of nanoparticles. The nonspecific portrait, on the other hand, will result in the
nonspecific binding of positively charged nanoparticles to the negatively charged cell
membrane, which might induce nonspecific delivery of siRNA that will drastically
reduce the therapeutic effect.
To overcome these problems, we propose to construct neutral and target-specific
AuNP/siRNA nanoplexes as the delivery system, the structure of which is shown in
Figure 6.

Figure 6. Structure of the proposed neutral AuPEI/siRNA/PEI-PEG-FA nanoplexes.
AuNP = gold nanoparticles, PEI = polyethylenimine, PEG = polyethylene glycol, FA =
folic acid
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Hypotheses and Objectives
The hypotheses are summarized as follows:
1.

The neutral character of the Au nanoplex will avoid the quick clearance

and cytotoxicity that caused by the cationic nature of previous synthesized AuNP/siRNA
complexes.
2.

PEGylation will stabilize the nanoplexes in biological media and prolong

their circulation time in blood stream so that the nanoplexes will have the sufficient time
to accumulate in tumor due to the EPR effect.
3.

Folic acid, served as the targeting group, would avoid the nonspecific

delivery of siRNA, so the side effect caused by lack of tumor selectivity would be greatly
reduced.
The basis of the first hypothesis comes from previous studies of stable nucleic
acid lipid particle and functionalized PEIs. The reduced positive-charged liposome or
polyplex have shown lower toxicity and surprisingly, in some cases, increased the
transfection efficiency. The second hypothesis is based on the widely accepted fact that
PEGlyation can increase the stability of different delivery systems (lipoplex, liposome,
polyplex, and gold nanoparticles) and decrease the nonspecific interactions with serum
protein and endothelium. The basis of the third hypothesis is that a variety of molecular
functionalities have been successfully linked to FA to achieve FR-targeted delivery to
tumor cells.
The objectives are summarized as follows:
1.
approach.

Assembly of AuPEI/siRNA/PEI-PEG-FA through Layer-by-Layer
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2.

Characterization of AuPEI/siRNA/PEI-PEG-FA by UV-vis spectrometry,

DLS and zeta potential.
3.

Evaluation of AuPEI/siRNA/PEI-PEG-FA in the FR+ cancer cell lines.
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CHAPTER III
MATERIALS AND METHODS
Experimental Protocols
Synthesis of PEI-PEG-FA and PEI-PEG-mPEG Copolymers
109 mg of mPEG-SH (Polysciences) was dissolved in 1 mL of dry DMSO
(Dimethyl sulfoxide, Fisher). To the mPEG-SH solution was added 70 ul of 318 mM
MCNSP in dry DMSO. The rxn was stirred once in a while at r.t. for 2 h. 220 mg of 10k
PEI (Polysciences) was dissolved in 600 ul in dry DMSO. Modified mPEG-MCNSP
solution was added dropwise to PEI solution in 1: 1, 1: 2, and 1: 4 ratios. After 1 h, three
conjugates were precipitated out by ether, re-dissolved in H2O, and dialyzed by 3500
MW membrane. Then the three copolymers were transferred into the 45-mL tubes,
frozen, lyophilized until dry, and stored at -20℃.
172 mg of FA-PEG-S-S-PEG-FA was dissolved in 3 mL of DMSO. 65 mg of
DTT (Dithilthreitol) were dissolved in 1 mL of DMSO. Then DTT solution was added to
the FA-PEG disulfide solution. The rxn was stirred at r.t. for 3 h. Then DTT was washed
away by ether. Then the FA-PEG-SH was re-dissolved in dry DMSO, and added 98 ul of
318 mM MCNSP to the solution. The rxn was stirred once in a while at r.t. for 2 h. 318
mg of 10k bPEI was dissolved in 1206 ul DMSO. Modified FA-PEG-MCNSP solution
was added dropwise to PEI solution in 1: 1, 1: 2, and 1: 4 ratios. After 1 h, three
conjugates were precipitated out by ether, re-dissolved in H2O, and dialyzed by 3500
MW membrane. Then the three copolymers were transferred into the 45-mL tubes,
frozen, lyophilized until dry, and stored at -20℃.
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In vitro Transcription of siGLuc-ppp and Tingle Strand RNA with 80 nt (ssRNA80)
In vitro transcription of siGLuc. Mix 10 ul of 10X buffer (1X), 10 ul of 100 mM
DTT (10 mM), 36 ul of 25 uM NTPs, 4 ul of DNA template, 1 ul of RNase inhibitor, and
10 ul of T7 polymerase in 30 ul of RNase-free water. The rxn mixture was incubated at
37℃ for 2 h. The crude siGLuc-ppp was obtained by ethanol precipitation and further
purified by 8% PAGE gel to get pure siGLuc-ppp.
In vitro transcription of ssRNA80. 5 ul of Sigma water, 2 ul of 10X buffer (1X), 2
ul of 100 mM DTT (10 mM), 6 ul of 25 mM NTP (7.5 mM), 2 ul of DNA template (1
ul/10 ul rxn), and 1 ul of RNase inhibitor was added to 500-ul tube. After vortex, 2 ul of
T7 RNA polymerase was added the mixture. The rxn was incubated at 37°C for 3 h. The
crude ssRNA80 was obtained by ethanol precipitation and further purified by 8% PAGE
gel to get pure RNA molecules.
Layer-by-Layer Assembly of AuPEI/siRNA/PEI-PEG-FA
AuNP (13nm diameter) were synthesized by the reduction of chorloauric acid
with a subsequent addition of citrate to precipitate gold ions into uncharged gold atoms,
as previously described. Branched polyethylenimine (HS-PEI1.8k (1.8kDa) and HS-PEI10k
(10kDa)) was synthesized by conjugation of 11-mercaptoundecanoic acid (MUA) with
PEI (Polysciences, Inc). HS-PEI1.8k was added to AuNPs at the final concentration of 0.5
mM, and the rxn was incubated at room temperature overnight. The thiol-modified
AuNPs (AuPEI) were purified six times by centrifugation and re-suspended in aqueous
solution. The purified AuPEI were added dropwise to the siRNA solution at room
temperature overnight at a ratio of 500: 1 (siRNA: AuNPs). Excess siRNA was removed
by 3x centrifugation (4.0 rcf, 80 min). The purified AuPEI/siRNA was added to the
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solution of PEI-PEG-FA (or PEI, PEI-mPEG) at the ratio of 200: 1 (Polymer:
AuPEI/siRNA). After 1x centrifugation (4.0 rcf, 20 min), the AuPEI/siRNA/PEI-PEI-FA
was ready for the cellular study. After the deposition of each layer, the Au nanoplexes
were characterized by UV-vis spectrometry, DLS (Dynamic light scattering), and zeta
potential.
Enzymatic Degradation of AuPEI/siRNA/PEI
The purified AuPEI/si-3/PEI nanoplexes (300 pmol siRNA) were treated with
Riboshredder RNase Blend (Epicenter Biotechnologies) (0.1 unit/500 ul RNase free
Ultra-pure water), and the absorbance at 260 nm was minored using an Agilent 8453 UVVisible spectrophotometer (Agilent Technologies) in “Kinetics” mode. The positive
control, siRNA-3 only (si-3, 300 pmol) was also treated with Riboshredder RNase Blend
at similar concentration. The spectrometer was blank with DNase/RNase Ultra pure water
(Life Technologies), and the absorbance at 260 nm was monitored for 300s, with 60 data
points acquired per minute.
Release of HS-PEI from AuPEI by DTT
HS-PEI-FITC was synthesized by the conjugation of FITC with HS-PEI. HS-PEIFITC was added to AuNPs at the final concentration of 1.0 mM, and the rxn was
incubated at room temperature overnight. The AuPEI-FITC were purified six times by
centrifugation and re-suspended in aqueous solution. DTT was then added to the Au
nanoplexes at various concentrations (100 mM, 200 mM, 500 mM, and 100 mM). The
rxns were incubated at 70℃ for 1 h and centrifuged to remove the aggregates. The
supernatant was measured by fluorescence spectroscopy, and the concentration of
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released HS-PEI-FITC was calculated from the standard curve, which was prepared with
a series of HS-PEI-FITC solution in the reaction condition.
Cell Culture
All the cell lines were maintained and proliferated in folate free RPMI 1640 cell
media supplemented with 10% fetal calf serum (FCS), 100 units per ml penicillin, and
100 ug per ml streptomycin at 37 °C in 95% air humidified atmosphere, and 5% CO2.
Three of them (KB, SKOV3 and HeLa) express high levels of folate receptor while A549
cells express little. A KB-GLuc cell line that permanently expresses the Gaussia
Luciferase is developed for the analysis of RNAi effects.
Downregulation of GLuc in KB-GLuc Cells by Au Nanoplexes
KB-GLuc cells were seeded in 48-well plates in folate free RPM1640
supplemented with 10% FBS 24 h before experiment. Dh/siGLuc-ppp was prepared
following the standard protocol.84 Then KB-GLuc cells were incubated with Dh/siGLucppp and Au nanoplexes for 48 h, and the medium supernatant was analyzed by GLuc
assay following the standard protocol.84 The concentration of siGLuc-ppp was 100 nM.
Targeted Delivery of ssRNA80 by Au Nanoplexes
KB-GLuc cells were seeded in 48-well plates in folate free RPM1640
supplemented with 10% FBS 24 h before experiment. Dh/ssRNA80 was prepared
following the standard protocol.84 The KB-GLuc cells were incubated with Dh/ssRNA80
and the Au nanoplexes for 2, 12 and 24 h in different culture media. Then all the media
was switched to 10% FBS RPMI1640. After 48 h, the cell viability was analyzed by
Toluidine blue (TB) assay.84
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Downregulation of Luc in HeLa Cells by Au Nanoplexes
HeLa cells were seeded in 48-well plates in folate free RPM1640 supplemented
with 10% FBS 24 h before experiment. Dh/pGL3 and Dh/siF17 was prepared following
the standard protocol.84 The KB-GLuc cells were first incubated with Dh/pGL3 for 1 h.
After another 5 h, the KB-GLuc cells were further incubated with Dh/siF17 and Au
nanoplexes for 6 h in different culture media. Then all the media was switched to 10%
FBS RPMI1640. After 42 h, the cells were analyzed by Luc assay.84
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CHAPTER IV
RESULTS
Layer-by-Layer Assembly of AuPEI/RNA/PEI-PEG-FA
To assemble the well-defined Au nanoplexes, the key is to avoid the aggregation
caused by interparticle bridging. The aggregation not only lowers the yields but also
makes their application in cell culture pointless. To develop the optimal procedure, each
step in the assembly process should be carefully investigated.
Preparation of AuPEI
Figure 7 describes how the HS-PEI concentration in the reaction affected the
hydrodynamic diameter, zeta potential, and size distribution of the purified AuPEI. When
the [HS-PEI] was above 0.3 mM, the Au nanoplexes exhibited similar size (23.2 to 24.3
nm), zeta potential (55.2 to 56.0 mV), and size distribution. Once [HS-PEI] dropped to
0.1 mM, the aggregates of Au nanoplexes were formed, which increased the diameter of
AuPEI to 45.8 nm and shifted the size distribution curve towards the large-size direction.
Despite their large size, the aggregates still possessed the similar zeta potential as the rest
of the Au nanoplexes.
Electrostatic repulsion is one major force that keeps the Au nanoplexes stable in
the aqueous solution. To prevent forming aggregations, the nanoplexes should have
enough surface charge to “push” other nanoplexes away. AuNPs are stabilized in solution
by a high concentration (~ 0.3 mM) of citrate, a negatively charged molecule near pH 7.
To overcome the charge and replace the citrate molecules completely, enough positivecharged HS-PEI should be added so that they can bind on the AuNPs and make them
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stable in the solution. If the critical concentration of HS-PEI is not met (e.g. [HS-PEI] =
0.1 mM), aggregations will be formed during the assembly process.
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Figure 7. Characterization of AuPEI prepared in different HS-PEI solutions. (A) The
effect of HS-PEI concentration on the hydrodynamic diameter of AuPEI after purification.
(B) The corresponding zeta potential. (C) The corresponding size distribution: 0.1 mM
(red), 0.3 mM (green), 1.0 mM (blue) and 3.0 mM (black). The error bar is standard
deviation.
The Effect of Centrifugal Force on the Recovery of AuPEI/RNA
The major challenges in the assembly of the AuPEI/RRNA are the low recovery
yield and the aggregation of the nanoplexes during purification. Centrifugal force and the
ratio between AuPEI and RNA molecules are the two factors controlling that process.
Using tRNA as the model molecule, Figure 8 describes how the centrifugal force affected
the re-suspension of the AuPEI/tRNA after one centrifugation. It is clear that the
absorbance of the re-suspended AuPEI/tRNA was increased as the centrifugal force
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decreased, indicating the low rcf could greatly avoid the aggregation of AuPEI/tRNA
during the purification process. The ratio effect is depicted in the next section.
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Figure 8. UV-vis spectra of the re-suspended AuPEI/tRNA (AuPEI/tRNA ratio was 1:
500) after 20 min centrifugation under different centrifugal force.
Preparation of AuPEI/RNA
To prepare aggregate-free AuPEI, the critical concentration should be reached.
Similarly, to successfully coat RNA on the AuPEI, the critical ratio between AuPEI and
RNA should be satisfied. The condition was investigated using tRNA as the model
molecule. When mixing AuPEI and tRNA in ratio 1: 200, almost all the particles were
precipitated out. Hence, the AuPEI/tRNA should be assembled in much higher
tRNA/AuPEI ratio.
Figure 9 describes how the ratio of AuPEI: tRNA affected the hydrodynamic
diameter, zeta potential, and size distribution of purified AuPEI/tRNA. When the ratio (1:
1000) was away from the critical ratio, the hydrodynamic diameter of AuPEI/tRNA was
only 30.8 nm, and when the ratio (1: 400) was close to the critical ratio, the diameter
(61.2 nm) was increased by two folds. Correspondingly, the size distribution of the
AuPEI/tRNA had a right shift towards large-size direction. Although the aggregates were
formed, the zeta potentials of the two species were still very close to -40 mV.
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Figure 9. Characterization of AuPEI/tRNA prepared with different AuPEI: tRNA ratios.
(A) The effect of AuPEI: tRNA ratio on the hydrodynamic diameter of AuPEI/tRNA
after purification. (B) The corresponding zeta potential. (C) The corresponding size
distribution: 1: 400 (green) and 1: 1000 (red). The error bar is standard deviation.
Preparation of AuPEI/tRNA/PEI-PEG
To assemble neutral AuPEI/RNA/PEI-PEG, AuPEI/tRNA and PEI-mPEG
(PEG/PEI ratio was 2) were used to explore the conditions. Figure 10 describes the
relationship between the zeta potential and the hydrodynamic diameter of the Au
nanoplexes. When the ratio was 1: 50, the nanoplexes stayed in neutral (3.1 mV);
however, its diameter reached 1303 nm, falling into micrometer range. When the ratio
increased to 1: 250, the nanoplexes were positive charged (42.5 mV), and the diameter
was only 61.4 nm. The distribution curve clearly showed the difference of the two
nanoplexes in size.
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Figure 10. Characterization of AuPEI/tRNA/PEI-mPEG prepared with different
AuPEI/tRNA: PEI-mPEG ratios. (A) The effect of AuPEI/tRNA: PEI-mPEG ratio on the
zeta potential of AuPEI/tRNA/PEI-mPEG after purification. (B) The corresponding
hydrodynamic diameter. (C) The corresponding size distribution: 1: 50 (green) and 1: 250
(red). The PEG/PEI ratio in the PEI-mPEG was 2. The error bar is standard deviation.
Then the other two PEI-mPEG copolymers were used as the third layer to
assemble the AuPEI/tRNA/PEI-mPEG. Figure 11 describes how different PEI-mPEG
copolymers affected hydrodynamic diameter and size distribution when all three species
were neutral (Figure 11A). Although the higher PEG/PEI ratio resulted in a smaller
hydrodynamic diameter and a left shift of the distribution curve, all the nanoplexes were
too large for the siRNA delivery (Figure 11B-C), and their tendency of forming
aggregates made them very unstable in the aqueous solution.
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Clearly, the PEGylation cannot stabilize the neutral AuPEI/RNA/PEI-PEG in the
aqueous solution, which also indicates that having enough charge on the surface of the
Au nanoplexes is the key for them to “survive” in the solution.
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Figure 11. Characterization of AuPEI/tRNA/PEI-mPEG prepared with different PEImPEG. (A) The effect of PEG/PEI ratio on the zeta potential of AuPEI/tRNA/PEI-mPEG
after purification. (B) The corresponding hydrodynamic diameter. (C) The corresponding
size distribution: PEG/PEI=1 (blue), PEG/PEI=2 (red) and PEG/PEI=4 (green). The error
bar is standard deviation.
Assembly of AuPEI/siRNA/PEI on Optimized Condition
Based on the above study, an optimized procedure was developed and applied for
assembling stable AuPEI/siRNA/PEI, and the successful deposition of each layer was
monitored by UV-vis spectra, DLS, and zeta potential measurements (shown in Figure
12A-D). Figure 11A details the increase of the hydrodynamic diameter of the Au
nanoplexes during coating, which increased from 12.9 ± 0.3 nm (AuNPs) to 48.2 ± 3.7
nm (AuPEI/siRNA/PEI). The corresponding reversal of the zeta potential, shown in
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Figure 12B, demonstrated the deposition of each layer. Figure 12C describes the UV-vis
spectra of the Au nanoplexes. The maximum wavelength of the plasmon resonance peak,
except the out PEI layer, had a red shift during coating. Additionally, the absorbance of
AuPEI/siRNA/PEI in 220 – 320 nm UV-vis spectra proved the coating of the siRNA in
the nanoplexes (Figure 12D).
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Figure 12．Characterization of Au nanoplexes during LbL assembly upon optimized
conditions. (A) UV-vis spectra (400-800 nm) of AuNPs, AuPEI, AuPEI/siRNA and
AuPEI/siRNA/PEI. (B) UV-vis spectra (220-800 nm) of AuPEI and AuPEI/siRNA/PEI.
(C) Hydrodynamic diameter of the corresponding Au nanoplexes. (D) Zeta potential of
the corresponding Au nanoplexes. The error bar is standard deviation.
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Surface Density of the Layers in AuPEI/RNA/PEI-PEG-FA Nanoplex
Before applying the AuPEI/siRNA/PEI-PEG-FA to bio systems, it is better to
know the number of RNA molecules that wrapped on the Au nanoplexes, or it is hard to
control the concentration of siRNA in the cellular experiments.
Surface Density of the First Layer HS-PEI
To determine the surface density of HS-PEI, we used a strategy that is illustrated
in Scheme 2. First, HS-PEI was labeled by FITC and coated on AuNPs following the
optimized procedure. Then the fluorescent labeled AuPEI-FITC was treated with DTT
solution in high concentrations. As a result, the HS-PEI-FITC molecules on the
nanoplexes were replaced by DTT, released into the solution, and the DTT coated Au
nanoparticles precipitated out from the solution. Finally, the released HS-PEI-FITC was
quantified by fluorescence spectroscopy.

Figure 13. Flowchart illustrating the determination of surface density of HS-PEI on
AuPEI.
Before determining the surface density of AuPEI-FITC, the standard curve of HSPEI-FITC were prepared (Figure 14A, R-square = 0.996), and the effects of and
temperature and DTT concentration (two major factors involved in the DTT replacement
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reaction) on fluorescence signals were studied. Shown in Figure 14B, within in 60 min,
the fluorescent counts of HS-PEI-FITC were relatively constant at various temperatures,
indicating the fluorescent labeled HS-PEI molecules were stable in the aqueous solution
even at high temperature. In DTT solution, due to the quenching effect, the fluorescent
counts of HS-PEI-FITC were decreased over the DTT concentration, and such an effect
reached to the maximum above 500 mM (Figure 14C). Within 200 mM, the decrease of
the counts were in a linear relationship with the DTT concentration (Figure 14D, Rsquare = 0.998).
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Figure 14. (A) Standard curve for quantification of the released HS-PEI-FITC from Au
nanoplexes. (B) The effect of temperature on the fluorescence signals. (C-D) The effect
of DTT concentration on the fluorescence signals. The error bar is standard deviation.
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Since the temperature had little influence on the fluorescence signals, the DTT
replacement reaction was conducted at 70℃. Figure 15 describes the kinetics of the
release of HS-PEI-FITC under various DTT concentrations. In 100-200 mM range
(Figure 15A), after 10 min, about 600 HS-PEI-FITC per Au nanoplex were replaced by
DTT. After 30 min, about 900 HS-PEI-FITC per nanoplex were replaced. The large error
bar in the 40 and 60 min made it hard to decide whether the curve reached to plateau or
not. The replacement reaction was further conducted in 500 and 1000 mM DTT (Figure
15B). Despite the large error bar, the curve growth was decreased over the time, and after
60 min, such growth almost stopped. The kinetic study suggested all the HS-PEI-FITC
were released from the AuPEI-FITC after 60 min incubation in 500 mM (or higher) DTT
solution. The surface density of PEI on AuPEI was determined to be 1000 ± 100 per Au
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Figure 15. Release of HS-PEI-FITC from AuPEI-FITC by DTT after different incubation
time. (A) Release of HS-PEI-FITC in 100 and 200 mM DTT. (B) Release of SH-PEI in
500 and 1000 mM DTT. The error bar is standard deviation.
Surface Density of RNA Layer
To determine the surface density of the RNA molecules, we applied a strategy
reported in the literature.55 The amount of the RNA wrapped around the AuPEI was
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calculated from the formula (amount of RNA added - amount of RNA removed during
purification).55 The concentration of the purified AuPEI/RNA was determined by UV-vis,
so their amount can also be calculated. The surface density of RNA equals the amount of
coated RNAs over the amount of Au nanoplexes.
Different RNAs (tRNA, siGLuc, and siRNA (antivirus)) were coated on AuPEI,
and their surface densities were calculated respectively (Figure 16). The results suggested
that the surface density was co-related with the nucleotide length of the RNA molecule.
AuPEI/tRNA (80 nt) has 150 tRNA per Au nanoplex while AuPEI/siGLuc (60 nt) had
~200. On AuPEI/siRNA (antivirus, 40 nt), the number was increased to ~290 per Au
nanoplex.
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Figure 16. The surface density of antivirus RNA (42 nt), siGLuc (60 nt) and tRNA (80 nt)
on AuPEI/RNA.
Protection of siRNA from RNase Degradation
Figure 17 showed the protection of siRNA from AuPEI/si-3/PEI in RNase
enzymes solution. The naked si-3 was used as a control, which exhibited an increase in
the absorbance at 260 nm (%) after RNase Riboshedder was added to the solution,
suggesting degradation of naked si-3. In contrast, the AuPEI/si-3/PEI samples treated
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with the RNase enzyme did not increase absorbance (%), indicating that the siRNA in the
nanoplexes remained intact.
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Figure 17. Absorbance at 260 nm (%) of si-3 and AuPEI/si-3/PEI in RNase solution.
Stability of Au Nanoplexes in Different Cell Culture Medium
The stability of Au nanoplexes in biological fluids is a requisite for their
application in the cell culture. AuPEI/tRNA/PEI-mPEG with various AuPEI/tRNA: PEImPEG ratios (1: 10, 1: 200 and 1: 500) were assembled, applied to different biological
media, and their behaviors were monitored by UV-vis spectroscopy.
All the nanoplexes can be divided into two groups based on their surface charge.
AuPEI/tRNA and AuPEI/tRNA/PEI-mPEG (1: 10) were negatively charged, and
AuPEI/tRNA/PEI-mPEG (1: 200) and AuPEI/tRNA/PEI-mPEG (1: 500) were positively
charged. In serum-free RPMI solution, the negative-charged Au nanoplexes aggregated
after 1 h incubation (Figure 18A-B) while almost half positive-charged species still
remained disaggregated (Figure 18C-D). In the serum containing RPMI solution, the
negative charged nanoplexes still aggregated, but the addition of FBS slowed down the
aggregation process, especially in 40% FBS RPMI (Figure 18A-B). The positive-charged
nanoplexes exhibited good stabilities in the FBS containing medium (Figure 18C-D).
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Hence, the positive-charged Au nanoplexes were qualified candidates for the cellular
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Figure 18. UV-vis spectra of Au nanoplexes in different media (serum free RPMI, 5%
FBS RPMI and 40% FBS RPMI). (A) The UV-vis spectra of AuPEI/tRNA. (B) The UVvis spectra of AuPEI/tRNA/PEI-mPEG (1: 10). (C) The UV-vis spectra of
AuPEI/tRNA/PEI-mPEG (1: 200). (D) The UV-vis spectra of AuPEI/tRNA/PEI-mPEG
(1: 500). The Au nanoplexes were incubated in the medium for 1 h and monitored by
UV-vis spectrometry.
After exposed to the 5% FBS RPMI, the AuPEI/tRNA/PEI-mPEG (1: 200) was
characterized by DLS and zeta potential measurements (shown in Figure 19). The size of
the nanoplexes increased from 48.2 ± 3.7 nm to 78.8 ± 3.4 nm, and the zeta potential
became near neutral (slightly negatively charged).
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Figure 19. Hydrodynamic diameter (A) and zeta potential (B) of AuPEI/tRNA/PEImPEG in 5% FBS RPMI. The Au nanoplexes were prepared in 1: 200 AuPEI/tRNA:
PEI-mPEG ratio.
Targeted Delivery of RNA by AuPEI/RNA/PEI-PEG-FA
Targeted Delivery of siGLuc and Downregulation of Gaussia Luciferase in KB-GLuc
Cells
siGLuc-ppp was synthesized via in vitro transcription and incorporated into the
Au nanoplexes following the optimized procedure. Using the DharmaFECT as the
positive control, siGLuc-ppp was delivered into KB-GLuc cells by the designed Au
nanoplexes. The expression of GLuc was monitored by GLuc assay to quantify the
delivery efficiency (Figure 20A). After 48 h, the gene silencing efficiency was ~ 60% for
Dh/siGLuc-ppp and was none for both AuPEI and AuPEI/siGLuc-ppp. However, no
apparent difference was observed between nanoplexes AuPEI/siGLuc-ppp/PEI-mPEG
(no gene silencing) and AuPEI/siGLuc-ppp/PEI-PEG-FA (~ 7%) in the presence of 8%
serum. AuPEI/siGLuc-ppp alone did not show any gene silencing, but when mixed with
DharmaFECT, the efficiency increased to ~86% (Figure 20C). The cell viability was
monitored by TB assay (Figure 20B). Dh/siGLuc leaded to 40% decrease in cell number,
but all the Au nanoplexes showed no cytotoxicity.
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Figure 20. Targeted delivery of siGLuc into KB-GLuc cells. (A) Downregulation of
GLuc in KB-GLuc cells by Au-based siGLuc-ppp nanoplexes. The [siGLuc-ppp] was
100 nM. After 24 h or 48 h, 10 ul of the culture supernatant was analyzed by GLuc assay.
(B) Cell viability of the corresponding Au nanoplexes. After 48 h (including the
incubation time), the cells were washed, fixed and stained with Toluidine Blue. Then the
cells were washed with 2% SDS solution, of which the absorbance at 630 nm was
measured. (C) Downregulation of GLuc in KB-GLuc cells by the mixture of
DharmaFECT and AuPEI/siGLuc-ppp. After 48 h, 10 ul of the culture supernatant was
analyzed by GLuc assay. The error bar is standard deviation.
Targeted Delivery of ssRNA80 in KB-GLuc Cells in Different Cell Media
ssRNA80 was demonstrated to have had strong cellular toxicity in cancer cells. To
confirm the result from GLuc downregulation study, ssRNA80 was synthesized and
assembled into Au nanoplexes following the optimized procedure. After transfection into
KB-GLuc cells, the cell viability was monitored by TB assay to quantify the delivery
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efficiency. Figure 21A describes the cytotoxicity of AuPEI/ssRNA/PEI in various media.
In 8% serum medium and Opti-MEM, AuPEI/ssRNA/PEI exhibited no delivery of
ssRNA while in the serum-free medium, the cell number was decreased by ~ 53%. Figure
21B describes how the outer layer of Au nanoplexes in serum-free medium affected the
cell viability. After 2 h incubation with AuPEI/ssRNA/PEI, the cytotoxicity in KB-GLuc
cells reached ~ 60%. AuPEI/ssRNA/PEI-mPEG showed no toxicity at all. For cells
treated with AuPEI/ssRNA/PEI-mPEG-FA, the toxicity was near ~ 20%.
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Figure 21. Delivery of ssRNA80 (100 nM) into KB-GLuc cells by AuPEI/ssRNA/PEI.
KB-GLuc cells were used as the control. The percentage in the figure represents the
serum concentration in the cell culture. Incubation time represents how long the cells
were incubated with Au nanoplexes. After 72 h (including the incubation time), the cells
were washed, fixed and stained with TB. Then the cells were washed with 2% SDS
solution, of which the absorbance at 630 nm was measured. The error bar is standard
deviation.
Targeted Delivery of siF17 into HeLa cells and Downregulation of Luciferase Expression
To further confirm the results from above, the targeted delivery of our Au
nanoplexes were investigated in HeLa cell line. Figure 23A describes gene silencing of
Luciferase of AuPEI/siF17/PEI in various media. After 42 h, the gene silencing
efficiency was ~ 9% for the AuPEI/siF17/PEI in the presence of 8% serum, ~ 41% in the
2% serum and ~ 76% in 0% serum. The gene silencing efficiency was greatly increased
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as the serum was removed from the medium. Figure 23B describes the gene silencing
efficiency of AuPEI/siF17/PEI-mPEG and AuPEI/siF17/PEI-PEG-FA in 8% and 0%
serum media. Although the AuPEI/siF17/PEI-mPEG exhibited no gene silencing in both
media, no apparent difference was observed between the none-FA nanoplexes and the FA
modified nanoplexes.
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Figure 22. (A) Downregulation of Luc in HeLa cells by AuPEI/siF17/PEI in different cell
media. (B) Downregulation of Luc in HeLa cells by AuPEI/siF17/PEI-PEG-FA in
different cell media. HeLa cells were used as the control. The [siF17] was 100 nM. The
percentage in the figure represents the serum concentration in the cell culture. After 42 h,
the cells were lysed and the extracts were analyzed by Luc assay. The error bar is
standard deviation.
The results of the RNA delivery by Au nanoplexes in the KB-GLuc and HeLa cell
lines indicated that the delivery by AuPEI/RNA/PEI was greatly dependent on the serum
content in the medium. They also suggested that PEGylation can perfectly prevent the
nonspecific delivery by AuPEI/RNA/PEI. The targeted delivery of RNA by
AuPEI/RNA/PEI-PEG-FA remained doubtful and needs further exploration.
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CHAPTER V
SUMMARY AND FUTURE DIRECTION

Major Findings and Significance
To assemble well-defined and disaggregated Au nanoplexes through Layer-byLayer approach, there existed the critical concentration for the deposited macromolecules
or critical ratio of the Au nanoplex: deposited macromolecules. If the requirement is not
stratified, the Au nanoplex tends to form aggregates.
High centrifugal force caused flocculation and a low recovery yield during the
purification process of the Au nanoplexes, especially when the electrostatic interaction
was the main force between the two layers. Purified under the optimized condition, the
recovery yield can reach near 90%, and the interparticle bridging and the flocculation can
be completely avoided.
A well-defined and mono-dispersed Au nanoplexes AuPEI/siRNA/PEI has been
successfully assembled and well characterized. The nanoplex had a hydrodynamic
diameter of 48.2 ± 3.7 nm and zeta potential of 53.3 mV. The surface density of the first
layer HS-PEI was ~ 1000 per particle. Versatility is one important advantage of the
developed nanoplexes. The siRNA middle layer can be expanded to any other RNA
molecules, even DNA molecules and the surface density depended on its nucleotide
length. Since the AuPEI had certain binding capacity, which came from the amine groups
on branched PEI, shorter RNA (or DNA) molecules tended to have a higher surface
density while longer ones bound less.
Our optimized Au nanoplexes can stabilize siRNA molecules and protect them
from RNase degradation. The reason is straightforward: siRNA molecules were in the
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middle of the two PEI layers, which acted as “walls” to inhibit the interaction of RNase
with the siRNA molecules.
Our optimized Au nanoplexes were stable in the in vitro cell culture medium in
presence of the serum, which provides the ground for their application in the in vitro
study.
In terms of siRNA delivery, the Au nanoplexes AuPEI/siRNA/PEI exhibited
excellent gene silencing efficiency in the absence of the serum during the transfection.
The serum in the medium stabilized the Au nanoplexes but also made the siRNA delivery
much less effective. Because the nanoplexes were positively charged, its strong
interaction with the serum protein prevented its further contact with the cell membrane,
so the delivery efficiency was greatly reduced.
In term of targeted delivery, PEGylation greatly reduced the nonspecific delivery
of siRNA caused by AuPEI/siRNA/PEI. With PEGylation, AuPEI/RNA/PEI-mPEG
showed almost no cytotoxicity (when RNA is ssRNA80) or no knockdown of the targeted
gene (when RNA is siGLuc-ppp or siF17). According to these results, their applications
in the targeted delivery became possible.
Major Issues and Discussions
1.

Neutral Au nanoplexes AuPEI/RNA/PEI-PEG are not stable in the

aqueous solution, not mentioning in the cell culture medium. The PEI-PEG copolymers
(PEG/PEI ratios are 1, 2, and 4) we applied here cannot provide enough repulsive force
against the hydrophobic interactions between the neutral nanoplexes. Low surface density
of the PEG on the neutral nanoplexes is the reason. Au nanoparticles with complete PEG
coating by covalent bond have been synthesized and studied both in vitro85 and in vivo.86
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One strategy to the issue is to raise the PEG/PEI ratio, but it will reduce the positive
charges on the PEI and affect the binding between AuPEI/RNA and PEI-PEG.
2.

The major issue is that even though the AuPEI/ssRNA80/PEI-PEG-FA

caused more cell death than its PEI-mPEG counterpart, Au nanoplexes
AuPEI/siRNA/PEI-PEG-FA (siRNA = siGLuc-ppp and siF17) showed no gene
knockdown efficiency in the presence nor absence of the serum during the transfection.
Strength of the receptor-ligand interactions, ligand density, the length as well as
rigidity of the spacer between the target molecule and anchor can strongly affect the final
equilibrium of receptor-mediated endocytosis.87 65 The cellular uptake could also be
mediated by the displacement of serum proteins by the receptors.88 High binding affinity
(Kd ~ 10-10 M) of folic acid for the folate receptor indicated the existence of strong FR
receptor-folic acid interaction.89 The failed delivery of siRNA by AuPEI/siRNA/PEI in
the presence of serum protein indicated its strong interactions with the serum proteins.
Such binding is so strong that the coated proteins are difficult to be replaced, exposing
the naked nanoparticles to the cell membrane. This also explains why no delivery took
place from AuPEI/siRNA/PEI-mPEG and AuPEI/siRNA/PEI-PEG-FA in the serumcontaining medium. In the serum-free medium, although AuPEI/siRNA/PEI showed
satisfied delivery efficiency and PEGylation inhibited the nonspecific delivery, targeted
delivery by AuPEI/siRNA/PEI-PEG-FA still remained unclear.
To figure this out, 1) the surface density of FA on the Au nanoplexes should be
known. For liposomes, a mole fraction of 0.03-0.5% folate-PEG was found to be optimal
for effective delivery.65 The existence of optimal folate-PEG is probably true for the Au
nanoplexes, too. Without knowing such information, any improvement is hard to be made.
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2) The length of the PEG spacer also needs to be explored. Having shorter PEG chain
(e.g., PEG2000) in the targeted liposomes achieved better tumor targeting than PEG3400
and PEG5000.65 3) Connecting FA to AuNPs through covalent linkage is proved to be an
efficient approach to achieve targeted delivery.90 91 92 Hence, conjugating PEG-FA on our
Au nanoplexes through Au-S covalent bond is worthy of investigation.
Future Directions
Fast fabrication, versatility, and ability for siRNA protection are the major
characters of our newly developed Au nanoplex system. The high gene silencing
efficiency in the absence of serum makes it an excellent delivery agent for negativecharged macromolecules in vitro. The low gene silencing efficiency in the presence of
serum hinders its application in vivo. How to reduce its strong interaction with serum
without sacrificing its stability in the culture medium is one of the future directions. The
application of the system in targeted delivery needs more exploration: the surface density
of the FA, the effect of PEG spacer, and the conjugation manner of PEG-FA, which are
definitely other interesting directions to pursue.
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